Company
ReNeuron Group PLC
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 1 of 15
ReNeuron focuses on exosome platform after restructuring
CustomEX is a platform that can be optimised for specific tissue targets and payloads
ReNeuron Group data points to effectiveness of its ground-breaking technology
The company attended an industry summit in Boston where it shared the findings of research on its CustomEx exosomes
ReNeuron Group names John Hawkins as chief financial officer in boardroom reshuffle
Hawkins joined ReNeuron in October 2014 as financial controller and was also appointed company secretary in June 2021
ReNeuron CEO: 'We have a great company that just needed a shake-up'
Catherine Isted joined the company just over a year ago - and there's been a whirlwind of activity since her arrival
ReNeuron recruits from within for CEO role
CFO Catherine Isted will take the hot seat after beating off external competition for the role